Epidermal growth factor receptor imaging in human head and neck cancer xenografts

  title={Epidermal growth factor receptor imaging in human head and neck cancer xenografts},
  author={Laura K van Dijk and Otto C Boerman and Johannes H.A.M. Kaanders and Johan Bussink},
  journal={Acta Oncologica},
  pages={1263 - 1267}
ABSTRACT Molecular imaging of specific biomarkers can have prognostic, predictive or monitoring value in head and neck squamous cell carcinoma (HNSCC). The epidermal growth factor receptor (EGFR) is involved in various radiation resistance mechanisms as it steers the pathways related to DNA damage repair, proliferation, hypoxia and apoptosis. Radiolabeled labeled F(ab’)2 fragments of the EGFR antibody cetuximab can be applied for non-invasive imaging of this receptor. Preclinical studies have… 

Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer

This study may suggest that uPAR and TF could potentially be attractive targets for molecular imaging and therapy in OSCC due to high positive expression rates and tumor-specific expression patterns.

Novel genetic alterations and their impact on target therapy response in head and neck squamous cell carcinoma

In the current review, it is emphasized that future treatment strategy in HNSCC will not solely be based on “synthetic lethality” approaches directed against overactivated genes, and biologic, genetic, and epigenetic alterations of H NSCC will be taken into consideration to guide the therapy.

Retrospective investigation of the prognostic value of the β1 integrin expression in patients with head and neck squamous cell carcinoma receiving primary radio(chemo)therapy

The study in a HNSCC patient cohort treated with primary radio(chemo)therapy does not reveal a prognostic value of β1 integrin expression, and additional clinical parameters were not significantly associated with overall survival.

Advances in Development of Radiometal Labeled Amino Acid-Based Compounds for Cancer Imaging and Diagnostics

This review provides an overview and critical evaluation of novel approaches in the designing of target-specific probes labeled with metal radionuclides for the diagnosis of most common death-causing cancers, published mainly within the last three years.

Current status and future perspectives of fluorescence-guided surgery for cancer

Techniques in fluorescence-guided surgery (FGS) are emerging that selectively illuminate cancer cells, enhancing the distinction between tumors and surrounding tissues with the potential for single-cell sensitivity.

Rethink radiotherapy – BIGART 2017

The present issue of Acta Oncologica contains studies presented at the 15th BiGART2017 conference, dedicated to aspects of Biology-Guided Adaptive Radiotherapy, which attracted more than 200 physicians, physicists, radiobiologists and other scientists with an active interest in this specific area.



Imaging of Epidermal Growth Factor Receptor Expression in Head and Neck Cancer with SPECT/CT and 111In-Labeled Cetuximab-F(ab′)2

The 111In-cetuximab-F(ab′)2 tracer to image EGFR targeting in vivo displays higher tumor-to-blood ratios early after injection than 111 in an HNSCC model, making it more suitable for EGFR visualization and potentially for selecting patients for treatment with EGFR inhibitors.

PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging

It is suggested that EGFR-targeting tracers can be used to monitor EGFR receptor expression in HNSCC and have the potential to noninvasively monitor cetuximab treatment and steer individualized treatment regimens.

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy †

An overview of the preclinical studies that have been performed with radiolabeled cetuximab for imaging and/or treatment of different tumor models suggests the integration of diagnosis, treatment and monitoring as a theranostic approach appears to be a promising strategy for improvement of individualized cancer treatment.

Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a head‐and‐neck squamous cell carcinoma model

This study suggests that, at optimal cetuximab imaging dose, 111In‐cetUXimab can be used for visualization of EGFR expression in head‐and‐neck squamous cell carcinoma using SPECT.

PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.

Clinically, this tracer has the potential to be used to determine cetuximab targeting of tumors and possibly to non-invasively monitor the response to EGFR-inhibitor treatment and is a promising PET tracer to determine expression of EGFR in vivo.

111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.

In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.

  • L. MilasK. Mason Z. Fan
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2000
It is concluded that C225 anti-EGFR antibody enhances tumor radioresponse by multiple mechanisms that may involve direct and indirect actions on tumor cell survival.